All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
For a triple-class refractory patient entering 4L therapy, how would you sequence BCMAxCD3 and GPRC5DxCD3 bispecifics?
Featured
Bookmark this article
During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Maximilian Merz, Leipzig University, Leipzig, DE. We asked, for a triple-class refractory patient entering 4L therapy, how would you sequence BCMA×CD3 (B-cell maturation antigen) and GPRC5D×CD3 (G protein-coupled receptor family C group 5 member D) bispecifics?
For a triple-class refractory patient entering 4L therapy, how would you sequence BCMAxCD3 and GPRC5DxCD3 bispecifics?
In this video interview, Maximilian Merz discusses approved BCMA- and GPRC5D-targeted bispecific antibodies elranatamab, teclistamab, and talquetamab. He outlines the adverse events and side effects related to each class of bispecific antibody, including the risk of infection and their impact on activities of daily living. Merz highlights individual patient factors, including lifestyle and hobbies, to determine an individualized treatment plan to maintain quality of life.
This interview is also available in German.
Your opinion matters
2 votes - 42 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox